Key Highlights

  • 0.19 is the consensus loss per share estimate for Eledon Pharmaceuticals (NASDAQ:ELDN), which is due to report third quarter 2026 results after the market closes on November 13, 2026, per the screener snapshot.
  • 31.6 million is the USD net loss for the second quarter of 2026, or 0.27 per share, versus 11.2 million and 0.13 a year earlier, with a 9.6 million non-cash Warrant Fair Value loss.
  • 88.8 million is the USD cash, equivalents and short-term investments at June 30, 2026, down from 133.3 million at December 31, 2025, which management says funds operations into the second quarter of 2027.
  • 600 patients are planned for the Phase 3 kidney transplant trial of tegoprubart, with initiation expected in late 2026 and a 52-week non-inferiority comparison against tacrolimus.

What Investors Expect From Eledon Pharmaceuticals (NASDAQ:ELDN) on November 13, 2026

Eledon Pharmaceuticals is listed to report third quarter 2026 results after the market closes (AMC) on November 13, 2026. Per the screener snapshot, the consensus estimate is a loss of 0.19 per share and the market Capitalization is USD 216.97 million. For comparison, the second quarter loss was 0.27 per share and the third quarter of 2025 loss was 0.21 per share on a net loss of USD 17.5 million. Warrant fair value changes can swing reported results sharply from quarter to quarter.

The Rationale: Last Reported Quarter and Management Outlook for Eledon Pharmaceuticals (NASDAQ:ELDN)

In the second quarter of 2026 Research and Development expense was USD 18.2 million versus USD 20.3 million a year earlier, general and administrative expense was USD 4.6 million, and total operating expenses were USD 22.9 million. Excluding warrant changes the net loss was USD 22.0 million. Management cited BESTOW data at 18 months showing mean eGFR of about 74 versus 61 for tacrolimus, no biopsy-proven acute rejection events in tegoprubart patients after six months versus seven events (9.4%) on tacrolimus, and 12 of 12 islet patients insulin-independent. No formal financial guidance was given.

Valuation, Liquidity and Risks for Eledon Pharmaceuticals (NASDAQ:ELDN)

Per the screener snapshot, Market Value is USD 216.97 million. Cash and short-term investments of USD 88.8 million compare with USD 93.4 million at September 30, 2025. Warrant liabilities rose to USD 40.0 million from USD 11.4 million at year end, and common shares outstanding were 80,891,404. As a clinical-stage company with no product Revenue found in published coverage, Eledon faces trial, regulatory and financing risk, and the Phase 3 start and any new capital raise could dilute holders. P/E is not meaningful given the losses.

Where Things Stand

Where things stand: Eledon Pharmaceuticals (NASDAQ:ELDN) reports third quarter 2026 results after the market closes on November 13, 2026, with a consensus loss of 0.19 per share and a market value of USD 216.97 million per the screener snapshot. The second quarter net loss was USD 31.6 million, cash was USD 88.8 million and management guided to a runway into the second quarter of 2027. Investors will watch for updates on the 600-patient Phase 3 kidney transplant trial planned for late 2026, islet cell and liver transplant studies, xenotransplantation guidance and financing plans. This article is informational and is not Investment advice.